{"id":"https://openalex.org/W2731378","doi":null,"title":"Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).","display_name":"Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).","alternate_titles":[],"publication_year":2013,"publication_date":"2013-03-01","ids":{"openalex":"https://openalex.org/W2731378","mag":"2731378","pmid":"https://pubmed.ncbi.nlm.nih.gov/23380020"},"language":"en","primary_location":{"id":"pmid:23380020","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23380020","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and experimental rheumatology","raw_type":"Clinical Trial, Phase III"},"parent_works":[],"lineage":["https://openalex.org/W2731378"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055492436","display_name":"Tomoyuki Imagawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoyuki Imagawa","raw_affiliation_strings":["Department of Paediatrics, Yokohama City University, Yokohama, Japan. timagawa@gmail.com","Department of Paediatrics, Yokohama City University, Yokohama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Paediatrics, Yokohama City University, Yokohama, Japan. timagawa@gmail.com","institution_ids":["https://openalex.org/I89630735"]},{"raw_affiliation_string":"Department of Paediatrics, Yokohama City University, Yokohama, Japan","institution_ids":["https://openalex.org/I89630735"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066821710","display_name":"Ryuta Nishikomori","orcid":"https://orcid.org/0000-0002-9407-6158","observed_orcids":["https://orcid.org/0000-0002-9407-6158"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryuta Nishikomori","raw_affiliation_strings":["Kyoto univ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyoto univ","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076824220","display_name":"Hidetoshi Takada","orcid":"https://orcid.org/0000-0002-0741-5060","observed_orcids":["https://orcid.org/0000-0002-0741-5060"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hidetoshi Takada","raw_affiliation_strings":["Faculty of Medical Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medical Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108359065","display_name":"Saoko Takeshita","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Saoko Takeshita","raw_affiliation_strings":["Yokohama City University,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yokohama City University,","institution_ids":["https://openalex.org/I89630735"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110721989","display_name":"Neha Patel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neha Patel","raw_affiliation_strings":["#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007758632","display_name":"Dennis S. Kim","orcid":"https://orcid.org/0000-0002-5707-2609","observed_orcids":["https://orcid.org/0000-0002-5707-2609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis Kim","raw_affiliation_strings":["#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112061019","display_name":"Karine Lheritier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karine Lheritier","raw_affiliation_strings":["#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113926933","display_name":"Toshio Heike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshio Heike","raw_affiliation_strings":["Kyoto univ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyoto univ","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102757339","display_name":"Toshiro Hara","orcid":"https://orcid.org/0000-0002-7686-0379","observed_orcids":["https://orcid.org/0000-0002-7686-0379"]},"institutions":[{"id":"https://openalex.org/I135598925","display_name":"Kyushu University","ror":"https://ror.org/00p4k0j84","country_code":"JP","type":"education","lineage":["https://openalex.org/I135598925"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshiro Hara","raw_affiliation_strings":["Kyushu University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyushu University","institution_ids":["https://openalex.org/I135598925"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110182317","display_name":"Shumpei Yokota","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shumpei Yokota","raw_affiliation_strings":["Yokohama City University,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yokohama City University,","institution_ids":["https://openalex.org/I89630735"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.9156,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.86300578,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"31","issue":"2","first_page":"302","last_page":"309"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11078","display_name":"Inflammasome and immune disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11078","display_name":"Inflammasome and immune disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/canakinumab","display_name":"canakinumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cryopyrin-associated-periodic-syndromes","display_name":"cryopyrin-associated periodic syndromes","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nlrp3-mutation","display_name":"NLRP3 mutation","score":0.7680000066757202},{"id":"https://openalex.org/keywords/interleukin-1beta","display_name":"IL-1\u03b2","score":0.8379999995231628},{"id":"https://openalex.org/keywords/autoinflammatory-disease","display_name":"autoinflammatory disease","score":0.8370000123977661},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.8650000095367432},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6349999904632568},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C2779725882","wikidata":"https://www.wikidata.org/wiki/Q3655009","display_name":"Canakinumab","level":4,"score":0.9966732263565063},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9830628633499146},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6046759486198425},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6029794812202454},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5869749188423157},{"id":"https://openalex.org/C2781304901","wikidata":"https://www.wikidata.org/wiki/Q4804182","display_name":"Aseptic meningitis","level":3,"score":0.47500360012054443},{"id":"https://openalex.org/C2779121184","wikidata":"https://www.wikidata.org/wiki/Q1166142","display_name":"Erythema","level":2,"score":0.4322625696659088},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39577600359916687},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3700813353061676},{"id":"https://openalex.org/C2781228260","wikidata":"https://www.wikidata.org/wiki/Q415411","display_name":"Anakinra","level":3,"score":0.3209034204483032},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3116968870162964},{"id":"https://openalex.org/C2781026528","wikidata":"https://www.wikidata.org/wiki/Q48143","display_name":"Meningitis","level":2,"score":0.29477256536483765},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2336069941520691}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018836","descriptor_name":"Inflammation Mediators","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056587","descriptor_name":"Cryopyrin-Associated Periodic Syndromes","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D056587","descriptor_name":"Cryopyrin-Associated Periodic Syndromes","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D056587","descriptor_name":"Cryopyrin-Associated Periodic Syndromes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D056587","descriptor_name":"Cryopyrin-Associated Periodic Syndromes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:23380020","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23380020","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical and experimental rheumatology","raw_type":"Clinical Trial, Phase III"},{"id":"mag:2731378","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23380020","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1775749144","https://openalex.org/W1824951714","https://openalex.org/W1893413863","https://openalex.org/W1984077936","https://openalex.org/W1991784386","https://openalex.org/W2024722082","https://openalex.org/W2039126859","https://openalex.org/W2048693099","https://openalex.org/W2068100000","https://openalex.org/W2076699951","https://openalex.org/W2081688358","https://openalex.org/W2091498005","https://openalex.org/W2107723834","https://openalex.org/W2218144971","https://openalex.org/W2321223292","https://openalex.org/W2416569313"],"related_works":["https://openalex.org/W2575445179","https://openalex.org/W2292774566","https://openalex.org/W4402927761","https://openalex.org/W2556888886","https://openalex.org/W2101834978","https://openalex.org/W2097647216","https://openalex.org/W2144016275","https://openalex.org/W2125374122","https://openalex.org/W4416417253","https://openalex.org/W2334778742"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Cryopyrin-associated":[1],"periodic":[2,36],"syndrome":[3],"(CAPS),":[4],"a":[5,50,109,152,155,225,252],"rare":[6],"hereditary":[7],"auto-inflammatory":[8],"disease,":[9],"is":[10,68],"associated":[11],"with":[12,31,35,65,83,108,149,219,260],"mutations":[13],"in":[14,19,28,80,145,170,199],"the":[15,69,74,127,194,208,236],"NLRP3":[16],"gene":[17],"resulting":[18],"elevated":[20],"interleukin-1\u03b2":[21],"(IL-1":[22],"\u03b2)":[23],"release.":[24],"CAPS":[25,92],"generally":[26],"occurs":[27],"early":[29],"childhood":[30],"most":[32],"patients":[33,82,93,107,130,148,166,211,259],"presenting":[34],"fever,":[37],"skin":[38],"rash,":[39],"osteoarthropathy,":[40],"aseptic":[41],"meningitis,":[42],"sensorineural":[43],"hearing":[44],"loss":[45],"and":[46,76,250],"optic":[47],"neuritis.":[48],"Canakinumab,":[49],"fully":[51],"human":[52],"anti-IL-1\u03b2":[53],"monoclonal":[54],"antibody":[55],"which":[56,217],"binds":[57],"selectively":[58],"to":[59,72,125,158,191],"IL-1\u03b2,":[60],"has":[61],"demonstrated":[62],"good":[63],"efficacy":[64,77],"CAPS.":[66,84,261],"This":[67],"first":[70],"study":[71,195],"evaluate":[73],"safety":[75],"of":[78,129,134,165,174,193,197,207],"canakinumab":[79,98],"Japanese":[81,91,258],"METHODS:":[85],"In":[86],"this":[87],"open-label":[88],"study,":[89],"19":[90],"aged":[94],"\u22652":[95],"years":[96],"received":[97],"either":[99],"150":[100,240],"mg":[101,241],"s.c.":[102,242],"or":[103,231],"2":[104],"mg/kg":[105],"for":[106,118,256],"body":[110],"weight":[111],"\u2264":[112],"40":[113],"kg":[114],"every":[115,243],"8":[116,244],"weeks":[117,245],"24":[119],"weeks.":[120],"The":[121,163],"primary":[122],"objective":[123],"was":[124,143,246],"assess":[126],"proportion":[128],"who":[131],"were":[132,169,233],"free":[133,173],"relapse":[135,175],"at":[136,176,201,205],"week":[137,177],"24.":[138,178],"RESULTS:":[139],"A":[140],"complete":[141],"response":[142],"achieved":[144],"18":[146],"(94.7%)":[147],"some":[150],"requiring":[151],"dose":[153],"and/or":[154],"frequency":[156],"adjustment":[157],"attain":[159],"full":[160],"clinical":[161],"response.":[162],"majority":[164],"(14/18;":[167],"77.8%)":[168],"remission,":[171],"i.e.":[172],"Auto-inflammatory":[179],"disease":[180],"activity":[181],"as":[182],"assessed":[183],"by":[184],"physician's":[185],"global":[186],"assessment":[187],"declined":[188],"from":[189],"baseline":[190,202],"end":[192,206],"(score":[196],"absent":[198],"10.5%":[200],"versus":[203],"31.6%":[204],"study).":[209],"Two":[210],"had":[212],"serious":[213],"adverse":[214],"events":[215],"(SAEs),":[216],"resolved":[218],"standard":[220],"treatment.":[221],"One":[222],"patient":[223],"reported":[224,234],"mild":[226],"injection-site":[227],"reaction.":[228],"No":[229],"malignancies":[230],"deaths":[232],"during":[235],"study.":[237],"CONCLUSIONS:":[238],"Canakinumab":[239],"well-tolerated,":[247],"highly":[248],"efficacious":[249],"offered":[251],"convenient":[253],"dosing":[254],"regimen":[255],"treating":[257]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2731378","counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
